Redx Pharma (LON:REDX) Stock Passes Below 50-Day Moving Average of $14.61

Shares of Redx Pharma Plc (LON:REDX) crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of GBX 14.61 ($0.18) and traded as low as GBX 11.42 ($0.14). Redx Pharma shares last traded at GBX 15 ($0.19), with a volume of 1,420,135 shares trading hands.

Redx Pharma Stock Up 31.6 %

The stock has a 50-day moving average of GBX 14.61 and a 200-day moving average of GBX 19.76. The company has a debt-to-equity ratio of 527.00, a current ratio of 1.11 and a quick ratio of 1.93. The firm has a market cap of £58.35 million, a price-to-earnings ratio of -150.00 and a beta of -0.53.

Insider Transactions at Redx Pharma

In other news, insider Lisa Anson bought 115,000 shares of the firm’s stock in a transaction on Tuesday, April 16th. The shares were purchased at an average cost of GBX 9 ($0.11) per share, with a total value of £10,350 ($13,002.51). 18.35% of the stock is currently owned by insiders.

Redx Pharma Company Profile

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.